Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

European Medicines Agency stories

Nov 13, 2026

Novo submits sickle cell drug for regulatory approval

Novo Nordisk has submitted a sickle cell disease drug for regulatory approval, a medicine acquired in a billion-dollar deal that the company views as a future blockbuster.

Nov 13, 2026·2 sources
00

Top claims

  • ▪Martin Holst Lange, chief scientific officer at Novo Nordisk, stated that etavopivat could provide a new disease-modifying treatment option for people living with sickle cell disease if approved
  • ▪The phase 3b HIBISCUS 2 trial is evaluating once-daily etavopivat against placebo in an expected 510 patients aged 12 and older with sickle cell disease
  • ▪On November 13, 2026, Novo Nordisk submitted a New Drug Application to the U.S. FDA and a Marketing Authorization Application to the EMA for etavopivat to treat sickle cell disease in patients aged 12 and older

Topics

Clinical trialsFast track designationHematologyDrug Policy, Pricing & ApprovalFDA drug approvalOrphan drug designationNovo NordiskPharmaceutical IndustryRare diseases

Related entities

United StatesSickle Cell diseaseEuropean Commission